These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 31279006)

  • 21.
    Guo R; Offin M; Brannon AR; Chang J; Chow A; Delasos L; Girshman J; Wilkins O; McCarthy CG; Makhnin A; Falcon C; Scott K; Tian Y; Cecchi F; Hembrough T; Alex D; Shen R; Benayed R; Li BT; Rudin CM; Kris MG; Arcila ME; Rekhtman N; Paik P; Zehir A; Drilon A
    Clin Cancer Res; 2021 Feb; 27(3):799-806. PubMed ID: 33172896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
    Yamaoka T; Ohba M; Arata S; Ohmori T
    J Vis Exp; 2017 Aug; (126):. PubMed ID: 28829429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.
    Gimenez-Xavier P; Pros E; Bonastre E; Moran S; Aza A; Graña O; Gomez-Lopez G; Derdak S; Dabad M; Esteve-Codina A; Hernandez Mora JR; Salinas-Chaparro D; Esteller M; Pisano D; Sanchez-Cespedes M
    Mol Cancer Ther; 2017 Jul; 16(7):1366-1376. PubMed ID: 28396363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
    Pecci F; Nakazawa S; Ricciuti B; Harada G; Lee JK; Alessi JV; Barrichello A; Vaz VR; Lamberti G; Di Federico A; Gandhi MM; Gazgalis D; Feng WW; Jiang J; Baldacci S; Locquet MA; Gottlieb FH; Chen MF; Lee E; Haradon D; Smokovich A; Voligny E; Nguyen T; Goel VK; Zimmerman Z; Atwal S; Wang X; Bahcall M; Heist RS; Iqbal S; Gandhi N; Elliott A; Vanderwalde AM; Ma PC; Halmos B; Liu SV; Che J; Schrock AB; Drilon A; Jänne PA; Awad MM
    Cancer Discov; 2024 Aug; 14(8):1440-1456. PubMed ID: 38564707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
    Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
    Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
    Tiedt R; Degenkolbe E; Furet P; Appleton BA; Wagner S; Schoepfer J; Buck E; Ruddy DA; Monahan JE; Jones MD; Blank J; Haasen D; Drueckes P; Wartmann M; McCarthy C; Sellers WR; Hofmann F
    Cancer Res; 2011 Aug; 71(15):5255-64. PubMed ID: 21697284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.
    Riedel R; Fassunke J; Tumbrink HL; Scheel AH; Heydt C; Hieggelke L; Scheffler M; Heimsoeth A; Nogova L; Michels S; Weber JP; Fischer RN; Eisert A; Westphal T; Schaufler D; Siemanowski J; Ihle MA; Wagener-Ryczek S; Castiglione R; Pappesch R; Rehker J; Jürgens J; Stoelben E; Bunck A; Kobe C; Merkelbach-Bruse S; Sos ML; Büttner R; Wolf J
    Eur J Cancer; 2023 Jan; 179():124-135. PubMed ID: 36521334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
    Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
    J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.
    Togashi Y; Mizuuchi H; Tomida S; Terashima M; Hayashi H; Nishio K; Mitsudomi T
    Lung Cancer; 2015 Dec; 90(3):590-7. PubMed ID: 26547802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Gou LY; Li AN; Yang JJ; Zhang XC; Su J; Yan HH; Xie Z; Lou NN; Liu SY; Dong ZY; Gao HF; Zhou Q; Zhong WZ; Xu CR; Wu YL
    Oncotarget; 2016 Aug; 7(32):51311-51319. PubMed ID: 27259997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
    PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
    Baldacci S; Kherrouche Z; Descarpentries C; Wislez M; Dansin E; Furlan A; Tulasne D; Cortot AB
    Rev Mal Respir; 2018 Oct; 35(8):796-812. PubMed ID: 30174236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
    Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
    Frampton GM; Ali SM; Rosenzweig M; Chmielecki J; Lu X; Bauer TM; Akimov M; Bufill JA; Lee C; Jentz D; Hoover R; Ou SH; Salgia R; Brennan T; Chalmers ZR; Jaeger S; Huang A; Elvin JA; Erlich R; Fichtenholtz A; Gowen KA; Greenbowe J; Johnson A; Khaira D; McMahon C; Sanford EM; Roels S; White J; Greshock J; Schlegel R; Lipson D; Yelensky R; Morosini D; Ross JS; Collisson E; Peters M; Stephens PJ; Miller VA
    Cancer Discov; 2015 Aug; 5(8):850-9. PubMed ID: 25971938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
    Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
    Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
    J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.
    Suda K; Mizuuchi H; Maehara Y; Mitsudomi T
    Cancer Metastasis Rev; 2012 Dec; 31(3-4):807-14. PubMed ID: 22736441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations.
    Yamaguchi M; Hirai S; Idogawa M; Uchida H; Sakuma Y
    Exp Cell Res; 2022 Apr; 413(2):113078. PubMed ID: 35189107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.